Revenue from brand-name medicines
23% of revenue from brand-name medicines reinvested in R&D
643 million boxes distributed
+ 2.9 increase in the volume of boxes distributed
96% of revenue from brand-name medicines generated outside France
Some key figures
31st
LARGEST PHARMACEUTICAL GROUP WORLDWIDE
2nd largest pharmaceutical Group in France.
5th leading pharmaceutical Group in cardiology worldwide
Source: IQVIA Analytics Link, September 2020
22,500
EMPLOYEES
(September 2020)
150
COUNTRIES
in which the Group’s medicines are distributed
23 %
OF REVENUE
from brand-name medicines invested in R&D in 2019/2020.
A word from …
OLIVIER LAUREAU, President of Servier
The health crisis has further bolstered our efforts to drive therapeutic progress.
Ambitious strategic objectives for 2025
€6,5 Bn
Reach €6.5 billion in sales
€1,3 Bn
Reach an EBITDA of €1.3 billion
€1 Bn
Reach €1 billion in sales in oncology
Launch one new molecular
entity every three years,
including one by 2025
Stay within or reach
a top three position
in each of our indications
Reach optimal
engagement of the teams
2019/2020 Financial Results
€3.285 Bn
€4.688 Bn
2019-2020 Group revenue
+3.6% annual growth (at constant exchange rates)
€1.403 Bn
Revenue form generic medicines
Biogaran : €876 m
Egis : €477 m
Autres : €50 m
539 million boxes distributed
+ 5.3% increase in the volume of boxes distributed
A governance model underpinned by independence and a long-term vision
A comprehensive range of health care solutions
Influence of a French group on the world stage
Perspective n°1
Accelerating therapeutic innovation
Perspective n°2
Acting for and with patients
Perspective n°3
Guaranteeing access to health care for all
Perspective n°4
Preparing production facilities for tomorrow
Perspective n°5
;)